Share on StockTwits

Albany Molecular Research (NASDAQ:AMRI) was upgraded by research analysts at McLean Capital Management from a “neutral” rating to a “buy” rating in a report released on Friday, Stock Ratings News reports.

Albany Molecular Research (NASDAQ:AMRI) traded up 4.10% on Friday, hitting $14.99. 864,078 shares of the company’s stock traded hands. Albany Molecular Research has a 52-week low of $7.75 and a 52-week high of $14.43. The stock’s 50-day moving average is $11.14 and its 200-day moving average is $11.78. The company has a market cap of $481.0 million and a price-to-earnings ratio of 36.00.

Albany Molecular Research (NASDAQ:AMRI) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.22 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.17 by $0.05. Analysts expect that Albany Molecular Research will post $0.77 EPS for the current fiscal year.

Separately, analysts at Sterne Agee downgraded shares of Albany Molecular Research from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 3rd. They now have a $12.00 price target on the stock, down previously from $15.00.

In other Albany Molecular Research news, major shareholder Stuart Cable unloaded 30,000 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $12.00, for a total value of $360,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Albany Molecular Research, Inc (NASDAQ:AMRI) provides scientific services, technologies and products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.